首页> 外文期刊>中华医学杂志(英文版) >Exploration of approaches to adjusting brand-name drug prices in Mainland of China: based on comparison and analysis of some brand-name drug prices of Mainland and Taiwan, China
【24h】

Exploration of approaches to adjusting brand-name drug prices in Mainland of China: based on comparison and analysis of some brand-name drug prices of Mainland and Taiwan, China

机译:探索调整中国内地名牌药品价格的方法:基于对中国大陆和台湾部分名牌药品价格的比较和分析

获取原文
获取原文并翻译 | 示例
       

摘要

Background Under the circumstance of the New Medical Reform in Mainland of China,lowering drug prices has become an approach to relieving increase of medical expenses,and lowering brand-name medication price is a key strategy.This study,by comparing and analyzing brand-name medication prices between Mainland of China and Taiwan,explores how to adjust brand-name medication prices in Mainland of China in the consideration of the drug administrative strategies in Taiwan.Methods By selecting brand-name drug with generic name and dose types matched in Mainland and Taiwan,calculate the average unit price and standard deviation and test it with the paired t-test.In the mean time,drug administrative strategies between Mainland and Taiwan are also compared systematically.Results Among the 70 brand-name medications with generic names and matched dose types,54 are at higher prices in Mainland of China than Taiwan,which is statistically significant in t-test.Also,among the 47 medications with all of matched generic names,dose types,and manufacturing enterprises,38 are at higher prices in Mainland than Taiwan,and the gap is also statistically significant in t-test.In Mainland of China,brand-name medication took cost-plus pricing and price-based price adjustment,while in Taiwan,brand-name medication took internal and external reference pricing and market-based price adjustment.Conclusions Brand-name drug prices were higher in Mainland of China than in Taiwan.The adjustment strategies of drug orices are scientific in Taiwan and are worth reference by Mainland of China.
机译:背景技术在中国内地新医改的背景下,降低药品价格已成为缓解医疗费用上涨的一种途径,降低名牌药品价格是一项关键策略。中国大陆和台湾之间的药品价格,探讨了如何根据台湾的药品管理策略调整中国大陆的品牌药品价格。方法:选择与大陆和台湾地区相匹配的通用名称和剂量类型的品牌药品在台湾地区,计算平均单价和标准差,并用配对t检验进行测试。同时,还系统地比较了台湾和大陆之间的药品管理策略。结果在70种具有通用名和相符名称的药品中在中国大陆,剂量类型54的价格高于台湾,这在t检验中具有统计学意义。此外,在47种药物中匹配的通用名称,剂量类型和制造企业的价格在大陆比台湾高38,在t检验中,差异也具有统计学意义。在中国大陆,名牌药品采用了成本加价格和价格基于价格的价格调整,而在台湾,品牌药采用内部和外部参考价以及基于市场的价格调整。结论中国大陆的品牌药价格高于台湾。在台湾,值得大陆参考。

著录项

  • 来源
    《中华医学杂志(英文版)》 |2014年第12期|2222-2228|共7页
  • 作者单位

    School of Pharmaceutical Science,Peking University,Beijing 100191,China;

    School of Public Health,Peking University,Beijing 100191,China;

    International Research Center of Medical Administration,Peking University,Beijing 100191,China;

    China National Center for Biotechnology Development(CNCBD),Beijing 100039,China;

    Institute of Pharmacology,National Yang-Ming University,Taipei,Taiwan 00222,China;

    School of Pharmaceutical Science,Peking University,Beijing 100191,China;

    International Research Center of Medical Administration,Peking University,Beijing 100191,China;

  • 收录信息 中国科学引文数据库(CSCD);中国科技论文与引文数据库(CSTPCD);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-19 03:59:05
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号